patients

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

June 09, 2025 16:05 ET  | Source: Lyell Immunopharma, Inc Mark J. Bachleda, PharmD, MBA appointed as independent member of…

7 months ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1…

7 months ago

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the European Commission (EC) has granted conditional marketing authorisation…

7 months ago

Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…

7 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

June 06, 2025 16:01 ET  | Source: Keros Therapeutics, Inc. LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,…

7 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 05, 2025 16:58 ET  | Source: Boundless Bio, Inc. SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio…

7 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

7 months ago

Foundation for Sarcoidosis Research Announces 2025 Global Virtual Sarcoidosis Summit United for Progress: A New Chapter in Sarcoidosis

CHICAGO, June 04, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to finding…

7 months ago

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…

7 months ago

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

7 months ago